Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one beclomethasone compound selected from beclomethasone and the pharmaceutically acceptable derivatives thereof and at least one long acting beta-2-agonist; (ii) a propellant component including 1,1-difluoroethane (HFA-152a); and (iii) glycerol.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: A pharmaceutical composition is described. The composition comprises at least one mometasone compound selected from mometasone, pharmaceutically acceptable salts of mometasone, prodrugs of mometasone, solvates of mometasone, solvates of pharmaceutically acceptable salts of mometasone and solvates of prodrugs of mometasone and a propellant component comprising 1,1-difluoroethane (R-152a). In a preferred embodiment, the composition further comprises at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol.

Abstract: A pharmaceutical composition is described. The composition comprises at least one mometasone compound selected from mometasone, pharmaceutically acceptable salts of mometasone, prodrugs of mometasone, solvates of mometasone, solvates of pharmaceutically acceptable salts of mometasone and solvates of prodrugs of mometasone and a propellant component comprising 1,1-difluoroethane (R-152a). In a preferred embodiment, the composition further comprises at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one beclomethasone compound selected from beclomethasone and the pharmaceutically acceptable derivatives thereof and at least one long acting beta-2-agonist; (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a); and (iii) glycerol.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one tiotropium compound selected from tiotropium and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one indacaterol compound selected from indacaterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A method of drying a fluid comprising a fluoropropene, which method comprises the step of contacting the fluid with a desiccant comprising a molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. A heat transfer device comprising a heat transfer fluid comprising a fluoropropene, and a desiccant comprising a molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. Preferably, the fluoropropene is R134yf or R-1225ye.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one pharmaceutically acceptable salt of giycopyrrolate; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

Abstract: A propellant filling apparatus (10) comprising a filling booth (11) for receiving within it one or more containers for filling with a propellant; a propellant inlet (12) to the filling booth (11) that is capable of supplying propellant into one or more containers within the filling booth (11) from a propellant supply; an inert gas inlet (13) supplying inert gas from an inert gas supply (14) into the filling booth (11), a discharge outlet (16) from the filling booth (11); an extraction fan (17) that is capable of adjusting its fan speed to maintain the pressure of gas in the filling booth (11) to be lower than atmospheric pressure; and an oxygen detector (27) that is capable of detecting levels of oxygen in the filling booth (11) and triggering circulation of inert gas in the filling booth (11) when the level of oxygen in the filling booth (11) falls below an oxygen threshold level.

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: A method of drying a fluid comprising a fluoropropene, which method comprises the step of contacting the fluid with a desiccant comprising a molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. A heat transfer device comprising a heat transfer fluid comprising a fluoropropene, and a desiccant comprising a molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. Preferably, the fluoropropene is R134yf or R-1225ye.

Abstract: A method of drying a fluid comprising a fluoropropene, which method comprises the step of contacting the fluid with a desiccant comprising molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. A heat transfer device comprising a heat transfer fluid comprising a fluoropropene, and a desiccant comprising a molecular sieve having openings which have a size across their largest dimension of from about 3 ? to about 5 ?. Preferably, the fluoropropene is R134yf or R-1225ye.

Abstract: A pharmaceutical composition is described. The composition comprises at least one mometasone compound selected from mometasone, pharmaceutically acceptable salts of mometasone, prodrugs of mometasone, solvates of mometasone, solvates of pharmaceutically acceptable salts of mometasone and solvates of prodrugs of mometasone and a propellant component comprising 1,1-difluoroethane (R-152a). In a preferred embodiment, the composition further comprises at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol.